Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment failure for patients with primary immune thrombocytopenia.

The monoclonal antibody (mAb) helped maintain safe platelet levels for a prolonged period, reducing patient reliance on ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...